An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab
Deruxtecan Monotherapy versus Treatment of Physician’s Choice in
Hormone Receptorpositive, HER2-negative Unresectable Locally Advanced or
Metastatic Breast Cancer (HERTHENA-Breast04)
Deruxtecan Monotherapy versus Treatment of Physician’s Choice in
Hormone Receptorpositive, HER2-negative Unresectable Locally Advanced or
Metastatic Breast Cancer (HERTHENA-Breast04)
Phase: Phase II-III clinical trials
Principal Investigator: Prof. Vernieri Claudio
Main Facility: Oncologia Medica 1
Drug: Patritumab Deruxtecan
Pathologies: Breast cancer
ClinicalTrials.gov: Read more about clinical trials
he study is a Phase III, multicenter, interventional, non-randomized, openlabel, single-arm clinical trial evaluating patients with advanced or metastatic breast cancer, specifically HR+/HER2- or HER2-low, who have previously been treated with standard therapies. The study design involves a single arm, in which patients receive patritumab deruxtecan, an antibody-drug conjugate (ADC) directed against HER3, administered intravenously. The objective of the study is to evaluate the drug's antitumor activity, in terms of objective response rate (ORR), as well as secondary parameters such as progression-free survival (PFS), duration of response (DoR), and safety profile.
Last update: 12/05/2026